Considerando-se a necessidade brasileira de se obterem fármacos a preços competitivos e usando tecnologia nacional, visamos sintetizar um fragmento do Indinavir empregando como material de partida a L-serina, um aminoácido natural de baixo custo. Desta maneira, desenvolvemos a seguinte rota, em 6 etapas: p-tosilação da serina, pelo uso de cloreto de p-tosila / NaOH; amidação da p-tosilserina, empregando-se o sal de terc-butilamônio da N-hidroxissuccinimida / DCC; ciclização da (S)-2-terc-butil-N-p-tosilserina, em condição de transferência de fase, com cloreto de p-tosila / carbonato de potássio / TEBAC; abertura regiosseletiva do anel da aziridina pela 3-picolilamina; N,N-bis-alquilação da resultante diamina, com triflato de vinildifenilsulfônio e destosilação da piperazina obtida, promovida por HBr 30%, em ácido acético. Deste modo, o fragmento (S)- N-terc-butil-4-(piridin-3-ilmetil)piperazina-2-carboxamida foi obtido em 7 % de rendimento global e pode ser usado em uma rota alternativa para a síntese do Indinavir. / Considering the Brazilian need to obtain drugs at competitive prices and using national technology, we aimed to synthesize a fragment of Indinavir using L-serine, an inexpensive natural amino acid. Thus, we developed the following route in 6 steps: p-tosylation of serine by using p-tosyl chloride / NaOH; amidation of p-tosylserine employing the N-hydroxisuccinimide terc-butylammonium salt / DCC; cyclization of (S)-2-terc-butyl-N-p-tosylserine under phase transfer catalysis with p-tosyl chloride / potassium carbonate / TEBAC; aziridine ring opening with 3-picolylamine; N,N-bisalkylation of the resulting diamine with vinyldiphenylsulfonium triflate and detosylation of the obtained piperazine promoted by HBr 30% in acetic acid. In this way, the (S)-N-terc-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide fragment was obtained in 7 % overall yield and can be used in an alternative route for the synthesis of Indinavir.

Considerando-se a necessidade brasileira de se obterem fármacos a preços competitivos e usando tecnologia nacional, visamos sintetizar um fragmento do Indinavir empregando como material de partida a L-serina, um aminoácido natural de baixo custo. Desta maneira, desenvolvemos a seguinte rota, em 6 etapas: p-tosilação da serina, pelo uso de cloreto de p-tosila / NaOH; amidação da p-tosilserina, empregando-se o sal de terc-butilamônio da N-hidroxissuccinimida / DCC; ciclização da (S)-2-terc-butil-N-p-tosilserina, em condição de transferência de fase, com cloreto de p-tosila / carbonato de potássio / TEBAC; abertura regiosseletiva do anel da aziridina pela 3-picolilamina; N,N-bis-alquilação da resultante diamina, com triflato de vinildifenilsulfônio e destosilação da piperazina obtida, promovida por HBr 30%, em ácido acético. Deste modo, o fragmento (S)- N-terc-butil-4-(piridin-3-ilmetil)piperazina-2-carboxamida foi obtido em 7 % de rendimento global e pode ser usado em uma rota alternativa para a síntese do Indinavir. / Considering the Brazilian need to obtain drugs at competitive prices and using national technology, we aimed to synthesize a fragment of Indinavir using L-serine, an inexpensive natural amino acid. Thus, we developed the following route in 6 steps: p-tosylation of serine by using p-tosyl chloride / NaOH; amidation of p-tosylserine employing the N-hydroxisuccinimide terc-butylammonium salt / DCC; cyclization of (S)-2-terc-butyl-N-p-tosylserine under phase transfer catalysis with p-tosyl chloride / potassium carbonate / TEBAC; aziridine ring opening with 3-picolylamine; N,N-bisalkylation of the resulting diamine with vinyldiphenylsulfonium triflate and detosylation of the obtained piperazine promoted by HBr 30% in acetic acid. In this way, the (S)-N-terc-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide fragment was obtained in 7 % overall yield and can be used in an alternative route for the synthesis of Indinavir.

Synthetic piperazines are chemically-produced compounds that contain a six-member ring with two opposing nitrogen atoms. Several piperazine derivatives, namely 1- benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)-piperazine (TFMPP), and 1-(3- chlorophenyl)-piperazine (mCPP), have fallen into the “designer drugs” category due to their increasing recreational use as a “legal” alternative to ecstasy (3,4-methylenedioxymethamphetamine). These compounds share similar stimulant and physiological effects with amphetamines which make them desirable to young adults in party-type atmospheres. BZP, a Schedule I drug for its high abuse potential and no accepted medical use, is the only recreationally-abused synthetic piperazine currently federally controlled in the United States. The purpose of this research was to develop and validate a reliable method to identify and quantify eight forensically significant synthetic piperazines in blood and urine using ultra-fast liquid chromatography-electrospray ionization-tandem mass spectrometry (UFLC-ESI-MS/MS). The method was validated according to the Scientific Working Group for Forensic Toxicologists (SWGTOX) guidelines for quantitative analysis for both matrices and includes the following analytes: 1-benzylpiperazine (BZP), 1-(4-fluorobenzyl)-piperazine (FBZP), 4-methyl-1-benzylpiperazine (MBZP), 1-(4-methoxyphenyl)-piperazine (MeOPP), 1-(para-fluorophenyl)-piperazine (pFPP), 1-(3-chlorophenyl)-piperazine (mCPP), 2,3-dichlorophenylpiperazine (DCPP), and 1-(3-trifluoromethylphenyl)-piperazine (TFMPP). All samples were prepared by fortifying 100 µL of certified drug-free whole blood and urine (UTAK Laboratories, Inc., Valencia, CA, U.S.A.) with certified reference standards (Cayman Chemical, Ann Arbor, MI, U.S.A.) of each analyte at desired concentrations and standard additions of 1-benzylpiperazine-d7, 1-(3-chlorophenyl)-piperazine-d8, and 1(-3-trifluoromethylphenyl)-piperazine-d4 internal standards (Cerilliant, Round Rock, TX, U.S.A). After pretreatment with 1 mL phosphate buffer, samples underwent solid phase extraction (SPE) on mixed-mode copolymeric columns (Clean Screen®, UCT Inc., Levittown, PA, U.S.A.). Eluents were evaporated to dryness with low heat (65°C) and nitrogen gas. Samples were reconstituted with a 50:50 mixture of methanol and 2mM ammonium formate buffer with 0.2% formic acid before being analyzed by a UFLC (Shimadzu Corporation, Kyoto, Japan) and 4000 QTRAP ESIMS/MS (SCIEX, Framingham, MA, U.S.A.) system. Analyses were performed with multiple reaction monitoring scans in positive ionization mode using ions and voltages obtained from a manual compound optimization. Analytes were separated on a reversed phase column (Kinetex® F5, Phenomenex®, Torrance, CA, U.S.A.) with a binary gradient consisting of a 2mM ammonium formate buffer with 0.2% formic acid and methanol with 0.1% formic acid. The flow rate was 0.400 mL/min. Analyst™ (SCIEX) software was used for data collection and MultiQuant™ (SCIEX) software was used for quantitation. The total run time was 11.5 minutes with equilibrations. All calibration curves in both matrices exhibited R2 values > 0.99 using a weighting factor of 1/x. A linear dynamic range of 20-2000 ng/mL was used for all analytes in both matrices, except for BZP in urine which ranged from 50-2000 ng/mL. In blood, the limit of quantitation was 10 ng/mL for mCPP and TFMPP and 20 ng/mL for BZP, FBZP, MBZP, MeOPP, pFPP and DCPP. In urine, the limit of quantitation was 10 ng/mL for MeOPP, mCPP, TFMPP and DCPP, 20 ng/mL for FBZP, MBZP and pFPP and 50 ng/mL for BZP. When a 200 ng/mL concentration was evaluated, the SPE procedure showed percent recoveries ranging from 80-95% for blood; except for BZP, FBZP, and MeOPP which had recoveries of 60%, 60%, and 105%, respectively. Percent recoveries ranged from 82-94% for urine; except for BZP and FBZP which had recoveries of 66% and 68%, respectively. Bias and precision were assessed at concentrations of 50, 200, and 700 ng/mL. All samples were calculated within ±20% bias and within ±20% coefficient of variation. The highest concentration evaluated that did not produce carryover in subsequent matrix blanks was 5000 ng/mL. Ionization was suppressed for all analytes in both matrices by 45-95%. Matrix effects were present but were determined to be insignificant. Of the drugs evaluated, caffeine, dibenzylpiperazine, and 1-(4-chlorophenyl)-piperazine (pCPP) produced chromatographic peaks in the method; however, pCPP was the only substance that affected quantitation of an analyte. It increased the peak area of mCPP by almost 50% when present at the same concentration which suggests this method is unable to differentiate between isomeric pairs. This is a sensitive, reliable, and robust method with a wide linear dynamic range to account for the presence of these analytes in both blood and urine. This research will provide for the identification and quantitation of these substances in forensic casework.

No description available.

No description available.

This work includes wetted wall column experiments that measure the CO₂ equilibrium partial pressure and liquid film mass transfer coefficient (kg') in 7, 9, 11, and 13 m MEA and 2, 5, 8, and 12 m PZ solutions. A 7 m MEA/2 m PZ blend was also examined. Absorption and desorption experiments were performed at 40, 60, 80, and 100°C over a range of CO₂ loading. Diaphragm diffusion cell experiments were performed with CO₂ loaded MEA and PZ solutions to characterize diffusion behavior. All experimental results have been compared to available literature data and match well. MEA and PZ spreadsheet models were created to explain observed rate behavior using the wetted wall column rate data and available literature data. The resulting liquid film mass transfer coefficient expressions use termolecular (base catalysis) kinetics and activity-based rate expressions. The kg' expressions accurately represent rate behavior over the very wide range of experimental conditions. The models fully explain rate effects with changes in amine concentration, temperature, and CO₂ loading. These models allow for rate behavior to be predicted at any set of conditions as long as the parameters in the kg' expressions can be accurately estimated. An Aspen Plus® RateSep™ model for MEA was created to model CO₂ flux in the wetted wall column. The model accurately calculated CO₂ flux over the wide range of experimental conditions but included a systematic error with MEA concentration. The systematic error resulted from an inability to represent the activity coefficient of MEA properly. Due to this limitation, the RateSep™ model will be most accurate when finetuned to one specific amine concentration. This Aspen Plus® RateSep™ model allows for scale up to industrial conditions to examine absorber or stripper performance. / text

Cryptosporidiosis is a common diarrheal disease caused by intestinal infection with the apicomplexan parasite Cryptosporidium, in humans usually either with C. hominis or C. parvum. Unfortunately, given a large burden of disease in children and immunocompromised people like AIDS patients, the only currently approved treatment, nitazoxanide, is unreliable for these patient populations. To address the urgent need for new drugs for the most vulnerable populations, large phenotypic screening efforts have been established to identify anti-Cryptosporidium growth inhibitors in vitro (hits). However, in the absence of a gold standard drug, the in vitro and in vivo characteristics that should be used to prioritize screening hits are not known. This thesis is focused on identifying promising anti-Cryptosporidium hits and drug leads, and using them to establish validated methods to guide hit-to-lead studies for anti-Cryptosporidium drug development. A re-analysis of our phenotypic screen of the Medicines for Malaria Venture Open Access Malaria Box identified a promising C. parvum growth inhibitor, MMV665917. It had similar in vitro activity against C. hominis, C. parvum Iowa, and C. parvum field strains, and it was amenable to preliminary structural activity relationship studies using commercially available variants, with one variant demonstrating nanomolar potency. Furthermore, MMV665917 was effective in vivo in an acute interferon-γ mouse model of cryptosporidiosis; and it appeared to cure an established infection in the chronic NOD SCID gamma (NSG) mouse model, unlike nitazoxanide, paromomycin, and clofazimine. We hypothesized that anti-Cryptosporidium activity in the highly immunocompromised chronic NSG mouse model might relate to compounds being capable of killing and eliminating parasites (cidal), rather than only preventing growth (static). To test this, we developed a novel in vitro parasite persistence assay that showed that MMV665917 was potentially cidal, whereas nitazoxanide, paromomycin and clofazimine appeared static. This pharmacodynamic assay also provided the concentration of compound required to maximize rate of parasite elimination, which could help design in vivo experiments. To further characterize compounds based on mechanism of action, we developed a range of in vitro medium-throughput life-stage assays. To validate and gain value from the assays, a “learner set” of compounds from our in-house screens and collaborations were tested in all of the in vitro assays and in the in vivo NSG mouse model. Using these assays, it was possible to group molecules based on chemical class/mechanism of action. Because compounds from distinct groups showed activity in the NSG mouse model, these methods could be used to obtain a diverse set of early-stage Cryptosporidium inhibitors for prioritization. Furthermore, compounds that appeared static in the in vitro parasite persistence assay did not have activity in the NSG mouse model. In summary, we report the identification and development of a highly promising initial lead, MMV665917, and report a range of in vitro assays that can be used to prioritize anti-Cryptosporidium hits and leads.

none

Zum gegenwärtigen Kenntnisstand bezüglich Solvatochromie, Sol-Gel Prozesse, und der Synthese von Polyketonen wird eine kurze Einführung gegeben. Die Synthesekonzeptionen funktionalisierter aromatischer Aminoketone wereden vorgestellt. Die neun Verbindungen wurden mittels Elementaranalyse, Röntgenstrukturanalyse, und spektroskopischen (NMR, UV/Vis, MS) Methoden aufgeklärt. Im Mittelpunkt der Untersuchungen steht die Untersuchung des Einflusses von unterschiedlichen Medien (Lösungmittel, Oberflächen, Sol-Gel Materialien und Nachbarnmoleküle im Kristall) auf die Lage der UV/Vis-Absorptionsmaxima verschiedener aromatischer Aminoketone. Die Ergebnisse der Untersuchungen liefern Informationen in Bezug auf das spezifische Solvatationsvermögen, die Polarität von Feststoffoberflächen, der Einfluss funktionaler Gruppen in aromatischen Aminoketonen auf die intermolekulare Wasserstoffbrückenbindungen in Kristallen, und über die Natur der Gast-Host-Wechselwirkungen. Auf der Basis von nucleophilen Substitutionsreaktionen wurden zwei verschiedene Prozesse für die Synthese von Ploy(benzophenone-co-piperazin) und der Kompositform entwickelt. Molekulare Strukturen und Eigenschaften konnten durch Elementaranalyse, mehrere spektroskopische (IR, Festkörper-NMR, UV/Vis, MALDI-TOF) Methoden, Zetapotentialmessungen in wässeriger Phase und thermogravimetrischen Bestimmungen charakterisiert werden.

Amine degradation in aqueous amine scrubbing systems for capturing CO₂ from coal fired power plants is a major problem. Oxygen in the flue gas is the major cause of solvent deterioration, which increases the cost of CO₂ capture due to reduced capacity, reduced rates, increased corrosion, solvent makeup, foaming, and reclaiming. Degradation also produces environmentally hazardous materials: ammonia, amides, aldehydes, nitramines, and nitrosamines. Thus it is important to understand and mitigate amine oxidation in industrial CO₂ capture systems. A series of lab-scale experiments was conducted to better understand the causes of and solutions to amine oxidation. This work included determination of rates, products, catalysts, and inhibitors for various amines at various conditions. Special attention was paid to understanding monoethanolamine (MEA) oxidation, whereas oxidation of piperazine (PZ) and other amines was less thorough. The most important scientific contribution of this work has been to show that amine oxidation in real CO₂ capture systems is much more complex than previously believed, and cannot be explained by mass transfer or reaction kinetics in the absorber by itself, or by dissolved oxygen kinetics in the cross exchanger. An accurate representation of MEA oxidation in real systems must take into account catalysts present (especially Mn and Fe), enhanced oxygen mass transfer in the absorber as a function of various process conditions, and possibly oxygen carriers other than dissolved oxygen in the cross exchanger and stripper. Strategies for mitigating oxidative degradation at low temperature, proposed in this and previous work are less effective or ineffective with high temperature cycling, which is more representative of real systems. In order of effectiveness, these strategies are: selecting an amine resistant to oxidation, reduction of dissolved metals in the system, reduction of the stripper temperature, reduction of the absorber temperature, and addition of a chemical inhibitor to the system. Intercooling in the absorber can reduce amine oxidation and improve energy efficiency, whereas amine oxidation should be considered in choosing the optimal stripper temperature. In real systems, 2-amino-2-methyl-1-propanol (AMP) is expected to be the most resistant to oxidation, followed by PZ and PZ derivatives, then methyldiethanolamine (MDEA), and then MEA. MEA oxidation with high temperature cycling is increased 70% by raising the cycling temperature from 100 to 120 °C, the proposed operational temperature range of the stripper. PZ oxidation is increased 100% by cycling to 150 °C as opposed to 120 °C. Metals are expected to increase oxidation in MEA and PZ with high temperature cycling by 40 - 80%. Inhibitor A is not expected to be effective in real systems with MEA or with PZ. MDEA is also not effective as an inhibitor in MEA, and chelating agents diethylenetriamine penta (acetic acid) (DTPA) and 2,5-dimercapto-1,3,4-thiadiazole (DMcT) are only mildly effective in MEA. Although MEA oxidation in real systems cannot be significantly reduced by any known additives, it can be accurately monitored on a continuous basis by measuring ammonia production from the absorber. Ammonia production was shown to account for two-thirds of nitrogen in degraded MEA at low temperature and with high temperature cycling, suggesting that it is a reliable indicator of MEA oxidation under a variety of process conditions. A proposed system, which minimizes amine oxidation while maintaining excellent rate and thermodynamic properties for CO₂ capture would involve use of 4 m AMP + 2 m PZ as a capture solvent with the stripper at 135 °C, intercooling in the absorber, and use of a corrosion inhibitor or continuous metals removal system. Reducing (anaerobic) conditions should be avoided to prevent excessive corrosion from occurring and minimize the amount of dissolved metals. This system is expected to reduce amine oxidation by 90-95% compared with the base case 7 m MEA with the stripper at 120 °C. / text